0001104659-22-081006.txt : 20220720 0001104659-22-081006.hdr.sgml : 20220720 20220720073638 ACCESSION NUMBER: 0001104659-22-081006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220720 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220720 DATE AS OF CHANGE: 20220720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 221092849 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm2221376d1_8k.htm FORM 8-K
0000001800 false Common Shares, Without Par Value ABT 0000001800 2022-07-20 2022-07-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2022-07-20 2022-07-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2022-07-20 2022-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

July 20, 2022

Date of Report (Date of earliest event reported)

  

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification  No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)

Name of Each Exchange
on Which Registered

Common Shares, Without Par Value ABT New York Stock Exchange
Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

  

Item 2.02 Results of Operations and Financial Condition

 

On July 20, 2022, Abbott Laboratories announced its results of operations for the second quarter 2022.

 

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, certain regulatory costs, certain litigation, the impairment of certain assets, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

 

Item 9.01Financial Statements and Exhibits

 

  Exhibit No. Exhibit

 

  99.1 Press Release dated July 20, 2022 (furnished pursuant to Item 2.02).

 

  104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
     
     
Date: July 20, 2022 By: /s/ Robert E. Funck, Jr.
    Robert E. Funck, Jr.
    Executive Vice President, Finance and Chief Financial Officer

 

 

 

EX-99.1 2 tm2221376d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

News Release

 

Abbott Reports Second-Quarter 2022 Results and Raises
Full-Year EPS Guidance

 

-Sales growth of 10.1 percent; organic sales growth of 14.3 percent

-GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent

-Global COVID-19 testing-related sales of $2.3 billion in the second quarter

-Continues to strengthen portfolio with new product approvals

 

 

 

ABBOTT PARK, Ill., July 20, 2022 — Abbott today announced financial results for the second quarter ended June 30, 2022.

 

Second-quarter sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis, which excludes the impact of foreign exchange.
GAAP diluted EPS1 was $1.14 in the second quarter. Excluding specified items, adjusted diluted EPS was $1.43, which reflects growth of 22.2 percent compared to the prior year.
Global COVID-19 testing-related sales were $2.3 billion in the second quarter.
Abbott is raising its full-year 2022 EPS guidance. Abbott projects full-year diluted EPS on a GAAP basis of at least $3.50 and projected adjusted diluted EPS of at least $4.90.
2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion, which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months.
In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients with slow heart rhythms. Aveir VR is the world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and was specifically designed to be expandable and retrievable when therapy needs evolve or the device needs to be replaced.
In May, Abbott announced U.S. FDA clearance of its FreeStyle Libre® 3 system, which automatically delivers up-to-the-minute glucose readings and unsurpassed 14-day accuracy2 in the world's smallest and thinnest3 wearable sensor.
In June, Abbott announced breakthrough device designation from the U.S. FDA for its first-of-its-kind glucose-ketone biowearable sensor development program, which will enable people with diabetes to continuously monitor glucose and ketones in one sensor, helping those at risk for developing a life-threatening complication called diabetic ketoacidosis.

 

"We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our new product pipeline has remained highly productive, and our diversified business has continued to be resilient in a challenging macro environment."

 

—more—

 

 

 

SECOND-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

 

Following are sales by business segment and commentary for the second quarter 2022:

 

Total Company

($ in millions)

 

               % Change vs. 2Q21 
   Sales 2Q22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   4,892    6,365    11,257    36.6    (4.2)   10.1    36.6    2.3    14.3 
Nutrition   761    1,192    1,953    (12.9)   (3.5)   (7.4)   (12.9)   1.5    (4.5)
Diagnostics   2,469    1,853    4,322    113.8    (11.4)   33.1    113.8    (5.6)   36.9 
Established Pharmaceuticals   --    1,223    1,223     n/a     3.7    3.7     n/a     9.2    9.2 
Medical Devices   1,660    2,097    3,757    7.9    (1.5)   2.5    7.9    7.1    7.5 

 

* Total Q2 2022 Abbott sales include Other Sales of approximately $2 million.

 

               % Change vs. 1H21 
   Sales 1H22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   9,829    13,323    23,152    32.5    0.5    12.0    32.5    6.7    15.9 
Nutrition   1,438    2,409    3,847    (15.9)   (1.1)   (7.2)   (15.9)   3.6    (4.4)
Diagnostics   5,210    4,398    9,608    86.4    (1.5)   32.3    86.4    4.3    35.9 
Established Pharmaceuticals   --    2,370    2,370     n/a     5.3    5.3     n/a     11.2    11.2 
Medical Devices   3,176    4,146    7,322    9.9    1.2    4.8    9.9    9.0    9.4 

 

* Total 1H 2022 Abbott sales include Other Sales of approximately $5 million.

 

n/a = Not Applicable.

 

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Second-quarter 2022 worldwide sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis.

 

Worldwide sales, excluding COVID-19 testing-related sales, decreased 0.3 percent on a reported basis and increased 4.1 percent on an organic basis in the quarter.4 Worldwide sales were negatively impacted by a voluntary recall and manufacturing shutdown initiated in February of certain infant formula products manufactured at one of Abbott's U.S. plants. Excluding COVID-19 testing-related sales and the U.S. sales associated with the recalled products in the current and prior years, total worldwide sales increased 1.6 percent on a reported basis and 6.2 percent on an organic basis in the second quarter. 5

 

—more—

2

 

 

Nutrition

($ in millions)

 

               % Change vs. 2Q21 
   Sales 2Q22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   761    1,192    1,953    (12.9)   (3.5)   (7.4)   (12.9)   1.5    (4.5)
Pediatric   413    512    925    (21.6)   (9.5)   (15.3)   (21.6)   (5.8)   (13.4)
Adult   348    680    1,028    0.5    1.6    1.2    0.5    7.6    5.2 

 

               % Change vs. 1H21 
   Sales 1H22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   1,438    2,409    3,847    (15.9)   (1.1)   (7.2)   (15.9)   3.6    (4.4)
Pediatric   751    1,021    1,772    (27.5)   (9.1)   (17.9)   (27.5)   (5.6)   (16.1)
Adult   687    1,388    2,075    2.1    5.8    4.6    2.1    11.5    8.3 

 

 

Worldwide Nutrition sales decreased 7.4 percent on a reported basis and 4.5 percent on an organic basis in the second quarter. Total worldwide Nutrition and Pediatric Nutrition sales were negatively impacted by a voluntary recall and manufacturing shutdown initiated in February of certain infant formula products manufactured at one of Abbott's U.S. plants. On July 1, Abbott restarted partial production at the facility. Excluding the U.S. sales associated with these products in the current and prior years, total worldwide Nutrition sales increased 0.5 percent on a reported basis and 3.8 percent on an organic basis in the second quarter.6

 

In Adult Nutrition, Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes nutrition brand, led to global sales growth of 1.2 percent on a reported basis and 5.2 percent on an organic basis.

 

—more—

3

 

 

 

Diagnostics 

($ in millions)

 

 

               % Change vs. 2Q21 
   Sales 2Q22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   2,469    1,853    4,322    113.8    (11.4)   33.1    113.8    (5.6)   36.9 
Core Laboratory   287    934    1,221    1.3    (8.6)   (6.5)   1.3    (2.0)   (1.3)
Molecular   71    141    212    (23.7)   (28.4)   (26.9)   (23.7)   (24.4)   (24.2)
Point of Care   101    38    139    3.2    (3.7)   1.2    3.2    0.3    2.4 
Rapid Diagnostics   2,010    740    2,750    195.4    (11.2)   81.7    195.4    (5.8)   84.6 

 

 

               % Change vs. 1H21 
   Sales 1H22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   5,210    4,398    9,608    86.4    (1.5)   32.3    86.4    4.3    35.9 
Core Laboratory   555    1,850    2,405    0.1    (4.3)   (3.4)   0.1    1.7    1.3 
Molecular   243    389    632    (9.4)   (16.9)   (14.2)   (9.4)   (12.4)   (11.3)
Point of Care   192    75    267    1.2    (1.7)   0.4    1.2    2.0    1.4 
Rapid Diagnostics   4,220    2,084    6,304    136.6    4.9    67.2    136.6    10.9    70.4 

 

 

Worldwide Diagnostics sales increased 33.1 percent on a reported basis and 36.9 percent on an organic basis in the second quarter. Global COVID-19 testing-related sales were $2.3 billion in the quarter, led by sales of testing products in Rapid Diagnostics.

 

 

Sales in Core Laboratory and Molecular Diagnostics were impacted by year-over-year declines in COVID-19 testing-related sales in these businesses. Excluding COVID-19 testing-related sales, Core Laboratory Diagnostics sales decreased 3.1 percent on a reported basis and increased 2.3 percent on an organic basis and Molecular Diagnostics sales increased 17.9 percent on a reported basis and 22.3 percent on an organic basis in the second quarter.7

 

—more—

4

 

 

Established Pharmaceuticals 

($ in millions)

 

 

               % Change vs. 2Q21
   Sales 2Q22   Reported  Organic
   U.S.   Int'l   Total   U.S.  Int'l   Total   U.S.  Int'l   Total 
Total   --    1,223    1,223    n/a   3.7    3.7    n/a   9.2    9.2 
Key Emerging Markets   --    931    931    n/a   1.8    1.8    n/a   7.1    7.1 
Other   --    292    292    n/a   10.3    10.3    n/a   16.7    16.7 

 

 

               % Change vs. 1H21
   Sales 1H22   Reported  Organic
   U.S.   Int'l   Total   U.S.  Int'l   Total   U.S.  Int'l   Total 
Total   --    2,370    2,370    n/a   5.3    5.3    n/a   11.2    11.2 
Key Emerging Markets   --    1,833    1,833    n/a   5.6    5.6    n/a   11.8    11.8 
Other   --    537    537    n/a   4.5    4.5    n/a   9.2    9.2 

 

 

Established Pharmaceuticals sales increased 3.7 percent on a reported basis and 9.2 percent on an organic basis in the second quarter.

 

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 1.8 percent on a reported basis and 7.1 percent on an organic basis, led by double-digit growth on a reported and organic basis in several geographies and therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management.

 

Other sales increased 10.3 percent on a reported basis and 16.7 percent on an organic basis in the quarter.

 

—more— 

5

 

 

Medical Devices 

($ in millions)

 

 

               % Change vs. 2Q21 
   Sales 2Q22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   1,660    2,097    3,757    7.9    (1.5)   2.5    7.9    7.1    7.5 
Rhythm Management   264    284    548    (2.3)   (4.4)   (3.4)   (2.3)   3.7    0.9 
Electrophysiology   226    260    486    8.6    (6.8)   (0.2)   8.6    2.2    5.0 
Heart Failure   179    62    241    6.5    4.2    5.9    6.5    13.6    8.3 
Vascular   228    425    653    (6.7)   (5.8)   (6.1)   (6.7)   1.2    (1.6)
Structural Heart   207    233    440    8.1    0.9    4.2    8.1    11.4    9.9 
Neuromodulation   157    40    197    (5.2)   (8.7)   (6.0)   (5.2)   0.2    (4.1)
Diabetes Care   399    793    1,192    37.8    3.4    12.8    37.8    12.4    19.4 

 

 

               % Change vs. 1H21 
   Sales 1H22   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   3,176    4,146    7,322    9.9    1.2    4.8    9.9    9.0    9.4 
Rhythm Management   512    560    1,072    0.3    (2.7)   (1.3)   0.3    4.4    2.5 
Electrophysiology   442    529    971    14.0    (0.1)   5.8    14.0    8.0    10.5 
Heart Failure   346    116    462    10.6    7.3    9.7    10.6    15.9    11.9 
Vascular   437    835    1,272    (6.0)   (3.7)   (4.5)   (6.0)   2.6    (0.4)
Structural Heart   397    454    851    10.4    3.4    6.5    10.4    12.8    11.7 
Neuromodulation   300    76    376    (3.4)   (9.1)   (4.6)   (3.4)   (0.9)   (2.9)
Diabetes Care   742    1,576    2,318    36.8    5.5    13.8    36.8    13.7    19.8 

 

 

Worldwide Medical Devices sales increased 2.5 percent on a reported basis and 7.5 percent on an organic basis in the second quarter. Sales growth was negatively impacted by reduced cardiovascular and neuromodulation procedure volumes as a result of recent surges of COVID-19 in several geographies, healthcare staffing challenges and lockdowns in China that were implemented to control the spread of the virus.

 

In Diabetes Care, FreeStyle Libre sales were approximately $1.1 billion in the quarter, which represents sales growth of 18.7 percent on a reported basis and 25.6 percent on an organic basis.

 

—more—

6

 

 

Abbott'S EARNINGS-PER-SHARE guidance

Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to at least $3.50. Abbott forecasts specified items for the full-year 2022 of $1.40 per share primarily related to intangible amortization, costs related to a voluntary recall, expenses associated with acquisitions, restructurings and cost reduction initiatives and other net expenses. Excluding specified items, Abbott is raising its projected adjusted diluted earnings per share to at least $4.90 for the full-year 2022.

 

Abbott declares 394TH consecutive QUARTERLY DIVIDEND

On June 10, 2022, the board of directors of Abbott declared the company's quarterly dividend of $0.47 per share. Abbott's cash dividend is payable Aug. 15, 2022, to shareholders of record at the close of business on July 15, 2022.

 

Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

 

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

 

 

 

 

 

 

 

—more—

7

 

 

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

 

     

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

 

Abbott Media:

Karen Twigg May, 224-668-2681

Kate Dyer, 224-668-9965

   
     

 

1All reported amounts relate to continuing operations only as there are no discontinued operations in the periods presented.
2Data on file, Abbott Diabetes Care. Comparison based on publicly available information.
3Among patient-applied sensors. Data on file, Abbott Diabetes Care.
4In the second quarter of 2022, COVID-19 testing-related sales were $2.324 billion. In the second quarter of 2021, total worldwide sales were $10.223 billion, which included COVID-19 testing-related sales of $1.267 billion.
5In the second quarter of 2022, U.S. sales of certain infant formula products were $116 million. In the second quarter of 2021, U.S. sales of certain infant formula products were $280 million.
6In the second quarter of 2021, worldwide Nutrition sales were $2.108 billion, which included $280 million of U.S. sales of certain infant formula products.
7In the second quarter of 2022, Core Laboratory and Molecular Diagnostics COVID-19 testing-related sales were $12 million and $75 million, respectively. In the second quarter of 2021, worldwide Core Laboratory and Molecular Diagnostics sales were $1.306 billion and $290 million, respectively. Core Laboratory and Molecular Diagnostics COVID-19 testing-related sales in the second quarter of 2021 were $58 million and $173 million, respectively.

 

 

 

 

 

 

 

—more—

8

 

 

Abbott Laboratories and Subsidiaries 

Condensed Consolidated Statement of Earnings

Second Quarter Ended June 30, 2022 and 2021

(in millions, except per share data)

(unaudited)

 

 

 

 

   2Q22   2Q21   % Change    
Net Sales  $11,257   $10,223    10.1    
                   
Cost of products sold, excluding amortization expense   4,933    4,947    (0.3)  1)
Amortization of intangible assets   507    504    0.7    
Research and development   684    654    4.8    
Selling, general, and administrative   2,757    2,726    1.1    
Total Operating Cost and Expenses   8,881    8,831    0.6    
                   
Operating Earnings   2,376    1,392    70.6    
                   
Interest expense, net   106    123    (14.1)   
Other (income) expense, net   (82)   (79)   3.6    
Earnings before taxes   2,352    1,348    74.4    
Taxes on earnings   334    159    109.2    
                   
Net Earnings  $2,018   $1,189    69.7    
                   
Net Earnings Excluding Specified Items, as described below  $2,542   $2,115    20.2   2)
                   
Diluted Earnings per Common Share  $1.14   $0.66    72.7    
                   
Diluted Earnings per Common Share,                  
excluding Specified Items, as described below  $1.43   $1.17    22.2   2)
                   
Average Number of Common Shares Outstanding                  
Plus Dilutive Common Stock Options   1,765    1,793         

 

 

 

 

 

 

NOTES: 
See tables on page 13 for an explanation of certain non-GAAP financial information.
See footnotes on the following page.

 

 

 

 

 

 

 

 

 

—more—

9

 

 

1)2021 Cost of products sold, excluding amortization expense includes approximately $500 million of charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the second quarter in projected testing demand.

 

2)2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $524 million, or $0.29 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions.

 

2021 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $926 million, or $0.51 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

 

—more—

10

 

 

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Half Ended June 30, 2022 and 2021

(in millions, except per share data)

(unaudited)

 

   1H22   1H21   % Change    
Net Sales  $23,152   $20,679    12.0    
                   
Cost of products sold, excluding amortization expense   9,920    9,348    6.1   1)
Amortization of intangible assets   1,019    1,013    0.6    
Research and development   1,381    1,308    5.6    
Selling, general, and administrative   5,544    5,509    0.6    
Total Operating Cost and Expenses   17,864    17,178    4.0    
                   
Operating Earnings   5,288    3,501    51.0    
                   
Interest expense, net   223    247    (9.9)   
Net foreign exchange (gain) loss   (3)   3    n/m    
Other (income) expense, net   (160)   (140)   14.5    
Earnings before taxes   5,228    3,391    54.2    
Taxes on earnings   763    409    86.5   2)
                   
Net Earnings  $4,465   $2,982    49.7    
                   
Net Earnings Excluding Specified Items, as described below  $5,619   $4,483    25.3   3)
                   
Diluted Earnings per Common Share  $2.51   $1.66    51.2    
                   
Diluted Earnings per Common Share,                  
excluding Specified Items, as described below  $3.16   $2.49    26.9   3)
                   
Average Number of Common Shares Outstanding                  
Plus Dilutive Common Stock Options   1,770    1,792         

 

 

 

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

 

—more— 

11

 

 

1)2021 Cost of products sold, excluding amortization expense includes approximately $500 million of charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the second quarter in projected testing demand.

 

2)2022 Taxes on Earnings includes the recognition of approximately $27 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $32 million in excess tax benefits associated with share-based compensation.
  
 2021 Taxes on Earnings includes the recognition of approximately $90 million in excess tax benefits associated with share-based compensation.

 

3)2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.154 billion, or $0.65 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions.
  
 2021 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.501 billion, or $0.83 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

  

—more— 

12

 

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Second Quarter Ended June 30, 2022 and 2021

(in millions, except per share data)

(unaudited)

 

   2Q22 
   As
Reported
(GAAP)
   Specified
Items
   As
Adjusted
   % to
Sales
 
Intangible Amortization  $507   $(507)  $--      
Gross Margin   5,817    563    6,380    56.7%
R&D   684    (32)   652    5.8%
SG&A   2,757    (14)   2,743    24.4%
Other (income) expense, net   (82)   (12)   (94)     
Earnings before taxes   2,352    621    2,973      
Taxes on Earnings   334    97    431      
Net Earnings   2,018    524    2,542      
Diluted Earnings per Share  $1.14   $0.29   $1.43      

 

Specified items reflect intangible amortization expense of $507 million and other net expenses of $114 million that includes costs associated with a product recall, acquisitions, and other net expenses. See page 16 for additional details regarding specified items.

 

   2Q21 
   As
Reported
(GAAP)
   Specified
Items
   As
Adjusted
   % to
Sales
 
Intangible Amortization  $504   $(504)  $--      
Gross Margin   4,772    1,048    5,820    56.9%
R&D   654    (18)   636    6.2%
SG&A   2,726    (90)   2,636    25.8%
Other (income) expense, net   (79)   35    (44)     
Earnings before taxes   1,348    1,121    2,469      
Taxes on Earnings   159    195    354      
Net Earnings   1,189    926    2,115      
Diluted Earnings per Share  $0.66   $0.51   $1.17      

 

Specified items reflect intangible amortization expense of $504 million and other net expenses of $617 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 17 for additional details regarding specified items.

 

—more— 

13

 

 

Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2022 and 2021
(in millions, except per share data)
(unaudited)

 

   1H22 
   As
Reported
(GAAP)
   Specified
Items
   As
Adjusted
   % to
Sales
 
Intangible Amortization  $1,019   $(1,019)  $--      
Gross Margin   12,213    1,199    13,412    57.9%
R&D   1,381    (65)   1,316    5.7%
SG&A   5,544    (53)   5,491    23.7%
Other (income) expense, net   (160)   (27)   (187)     
Earnings before taxes   5,228    1,344    6,572      
Taxes on Earnings   763    190    953      
Net Earnings   4,465    1,154    5,619      
Diluted Earnings per Share  $2.51   $0.65   $3.16      

 

Specified items reflect intangible amortization expense of $1.019 billion and other net expenses of $325 million that includes costs associated with a product recall, acquisitions, and other net expenses. See page 18 for additional details regarding specified items. 

 

   1H21 
   As
Reported
(GAAP)
   Specified
Items
   As
Adjusted
   % to
Sales
 
Intangible Amortization  $1,013   $(1,013)  $--      
Gross Margin   10,318    1,597    11,915    57.6%
R&D   1,308    (46)   1,262    6.1%
SG&A   5,509    (244)   5,265    25.5%
Other (income) expense, net   (140)   23    (117)     
Earnings before taxes   3,391    1,864    5,255      
Taxes on Earnings   409    363    772      
Net Earnings   2,982    1,501    4,483      
Diluted Earnings per Share  $1.66   $0.83   $2.49      

 

Specified items reflect intangible amortization expense of $1.013 billion and other net expenses of $851 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 19 for additional details regarding specified items.

 

—more—

14

 

 

A reconciliation of the second-quarter tax rates for 2022 and 2021 is shown below:

 

   2Q22 
($ in millions)  Pre-Tax
Income
   Taxes on
Earnings
   Tax
Rate
 
As reported (GAAP)  $2,352   $334    14.2%
Specified items   621    97      
Excluding specified items  $2,973   $431    14.5%

 

   2Q21 
($ in millions)  Pre-Tax
Income
   Taxes on
Earnings
   Tax
Rate
 
As reported (GAAP)  $1,348   $159    11.9%
Specified items   1,121    195      
Excluding specified items  $2,469   $354    14.4%

 

A reconciliation of the year-to-date tax rates for 2022 and 2021 is shown below: 

 

   1H22    
($ in millions)  Pre-Tax
Income
   Taxes on
Earnings
   Tax
Rate
    
As reported (GAAP)  $5,228   $763    14.6%  1)
Specified items   1,344    190         
Excluding specified items  $6,572   $953    14.5%   

 

   1H21    
($ in millions)  Pre-Tax
Income
   Taxes on
Earnings
   Tax
Rate
    
As reported (GAAP)  $3,391   $409    12.1%  2)
Specified items   1,864    363         
Excluding specified items  $5,255   $772    14.7%   

 

1)2022 Taxes on Earnings includes the recognition of approximately $27 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $32 million in excess tax benefits associated with share-based compensation.

 

2)2021 Taxes on Earnings includes the recognition of approximately $90 million in excess tax benefits associated with share-based compensation.

 

—more—

15

 

 

Abbott Laboratories and Subsidiaries
Details of Specified Items 
Second Quarter Ended June 30, 2022
(in millions, except per share data)
(unaudited)

 

 

   Acquisition or
Divestiture-
related (a)
   Restructuring
and Cost
Reduction
Initiatives (b)
   Intangible
Amortization
   Other (c)   Total
Specifieds
 
Gross Margin  $20   $(6)  $507   $42   $563 
R&D   (5)   --    --    (27)   (32)
SG&A   (7)   --    --    (7)   (14)
Other (income) expense, net   (4)   --    --    (8)   (12)
Earnings before taxes  $36   $(6)  $507   $84    621 
Taxes on Earnings (d)                       97 
Net Earnings                      $524 
Diluted Earnings per Share                      $0.29 

 

The table above provides additional details regarding the specified items described on page 13.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.

 

c)Other includes costs related to a voluntary recall within the Nutrition segment and incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

—more—

16

 

 

Abbott Laboratories and Subsidiaries

 

Details of Specified Items

 

Second Quarter Ended June 30, 2021

 

(in millions, except per share data)

 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)
   Restructuring
and Cost
Reduction
Initiatives (b)
   Intangible
Amortization
   Other (c)   Total
Specifieds
 
Gross Margin  $21   $510   $504   $13   $1,048 
R&D   (3)   1    --    (16)   (18)
SG&A   (18)   2    --    (74)   (90)
Other (income) expense, net   (3)   --    --    38    35 
Earnings before taxes  $45   $507   $504   $65    1,121 
Taxes on Earnings (d)                       195 
Net Earnings                      $926 
Diluted Earnings per Share                      $0.51 

 

The table above provides additional details regarding the specified items described on page 13.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the second quarter in projected testing demand.

 

c)Other includes costs related to certain litigation and the impairment of an intangible asset, as well as a gain on the disposition of an equity method investment.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

—more—

17

 

 

Abbott Laboratories and Subsidiaries

 

Details of Specified Items

 

First Half Ended June 30, 2022

 

(in millions, except per share data)

 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)
   Restructuring
and Cost
Reduction
Initiatives (b)
   Intangible
Amortization
   Other (c)   Total
Specifieds
 
Gross Margin  $41   $(12)  $1,019   $151   $1,199 
R&D   (7)   (1)   --    (57)   (65)
SG&A   (18)   --    --    (35)   (53)
Other (income) expense, net   (11)   --    --    (16)   (27)
Earnings before taxes  $77   $(11)  $1,019   $259    1,344 
Taxes on Earnings (d)                       190 
Net Earnings                      $1,154 
Diluted Earnings per Share                      $0.65 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.

 

c)Other includes charges related to a voluntary recall within the Nutrition segment and incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

 

d)Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years.

 

—more—

18

 

 

Abbott Laboratories and Subsidiaries

 

Details of Specified Items

 

First Half Ended June 30, 2021

 

(in millions, except per share data)

 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)
   Restructuring
and Cost
Reduction
Initiatives (b)
   Intangible
Amortization
   Other (c)   Total
Specifieds
 
Gross Margin  $40   $529   $1,013   $15   $1,597 
R&D   (5)   1    --    (42)   (46)
SG&A   (31)   1    --    (214)   (244)
Other (income) expense, net   (3)   1    --    25    23 
Earnings before taxes  $79   $526   $1,013   $246    1,864 
Taxes on Earnings (d)                       363 
Net Earnings                      $1,501 
Diluted Earnings per Share                      $0.83 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the second quarter in projected testing demand.

 

c)Other primarily relates to the costs related to certain litigation, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

# # # 

 

19

 

EX-101.SCH 3 abt-20220720.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20220720_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 abt-20220720_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 abt-20220720_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2221376d1_ex99-1img003.jpg GRAPHIC begin 644 tm2221376d1_ex99-1img003.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 20, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 20, 2022
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Central Index Key 0000001800
Entity Tax Identification Number 36-0698440
Entity Incorporation, State or Country Code IL
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
XML 9 tm2221376d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2022-07-20 2022-07-20 0000001800 us-gaap:CommonStockMember exch:XCHI 2022-07-20 2022-07-20 0000001800 us-gaap:CommonStockMember exch:XNYS 2022-07-20 2022-07-20 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2022-07-20 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 22 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2221376d1_8k.htm abt-20220720.xsd abt-20220720_def.xml abt-20220720_lab.xml abt-20220720_pre.xml tm2221376d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2221376d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20220720_def.xml" ] }, "inline": { "local": [ "tm2221376d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20220720_lab.xml" ] }, "presentationLink": { "local": [ "abt-20220720_pre.xml" ] }, "schema": { "local": [ "abt-20220720.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20220720", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221376d1_8k.htm", "contextRef": "From2022-07-20to2022-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221376d1_8k.htm", "contextRef": "From2022-07-20to2022-07-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-081006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-081006-xbrl.zip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